ORGANOGENESIS HOLDINGS INC (ORGO) Stock Price, Quote, News and Overview
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
ORGO Quote, Performance and Key Statistics
NASDAQ:ORGO (5/16/2025, 10:35:51 AM)
3.05
+0.02 (+0.66%)
The current stock price of ORGO is 3.05 USD. In the past month the price decreased by -28.71%. In the past year, price increased by 10.58%.
ORGO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.78 | 323.06B | ||
| AMGN | AMGEN INC | 13.07 | 145.90B | ||
| GILD | GILEAD SCIENCES INC | 13.16 | 126.78B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.29 | 63.57B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.52B | ||
| ARGX | ARGENX SE - ADR | 95.55 | 34.25B | ||
| ONC | BEIGENE LTD-ADR | 5.69 | 24.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.24B | ||
| NTRA | NATERA INC | N/A | 20.36B | ||
| BIIB | BIOGEN INC | 7.85 | 18.19B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.19B |
Related stock screener links
About ORGO
Company Profile
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 869 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Company Info
ORGANOGENESIS HOLDINGS INC
85 Dan Rd
Canton MASSACHUSETTS 02021 US
CEO: Gary S. Gillheeney Sr.
Employees: 869
Phone: 17815750775
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
What is the stock price of ORGANOGENESIS HOLDINGS INC today?
The current stock price of ORGO is 3.05 USD. The price increased by 0.66% in the last trading session.
What is the ticker symbol for ORGANOGENESIS HOLDINGS INC stock?
The exchange symbol of ORGANOGENESIS HOLDINGS INC is ORGO and it is listed on the Nasdaq exchange.
On which exchange is ORGO stock listed?
ORGO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORGANOGENESIS HOLDINGS INC stock?
10 analysts have analysed ORGO and the average price target is 6.12 USD. This implies a price increase of 100.66% is expected in the next year compared to the current price of 3.05. Check the ORGANOGENESIS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORGANOGENESIS HOLDINGS INC worth?
ORGANOGENESIS HOLDINGS INC (ORGO) has a market capitalization of 386.89M USD. This makes ORGO a Small Cap stock.
How many employees does ORGANOGENESIS HOLDINGS INC have?
ORGANOGENESIS HOLDINGS INC (ORGO) currently has 869 employees.
What are the support and resistance levels for ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a support level at 3.02 and a resistance level at 5.25. Check the full technical report for a detailed analysis of ORGO support and resistance levels.
Is ORGANOGENESIS HOLDINGS INC (ORGO) expected to grow?
The Revenue of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to grow by 4.27% in the next year. Check the estimates tab for more information on the ORGO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORGANOGENESIS HOLDINGS INC (ORGO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORGO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORGO, evaluating the profitability, health, valuation and growth aspects
- ORGANOGENESIS HOLDINGS INC (ORGO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORGANOGENESIS HOLDINGS INC (ORGO) Sales and EPS estimates to see what analysts future expectations are.
- ORGANOGENESIS HOLDINGS INC (ORGO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORGANOGENESIS HOLDINGS INC (ORGO) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORGANOGENESIS HOLDINGS INC (ORGO) Stock Chart to make your own analysis
- ORGANOGENESIS HOLDINGS INC (ORGO) Latest news and press-releases to stay up to date.
Does ORGANOGENESIS HOLDINGS INC (ORGO) stock pay dividends?
ORGO does not pay a dividend.
When does ORGANOGENESIS HOLDINGS INC (ORGO) report earnings?
ORGANOGENESIS HOLDINGS INC (ORGO) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of ORGANOGENESIS HOLDINGS INC (ORGO)?
The PE ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 33.89. This is based on the reported non-GAAP earnings per share of 0.09 and the current share price of 3.05 USD. Check the full fundamental report for a full analysis of the valuation metrics for ORGO.
What is the Short Interest ratio of ORGANOGENESIS HOLDINGS INC (ORGO) stock?
The outstanding short interest for ORGANOGENESIS HOLDINGS INC (ORGO) is 17.44% of its float. Check the ownership tab for more information on the ORGO short interest.
ORGO Technical Analysis
ORGO Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ORGO. ORGO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
ORGO Financial Highlights
Over the last trailing twelve months ORGO reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 125% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.19% | ||
| ROE | -0.24% | ||
| Debt/Equity | 0 |
ORGO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ORGO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -77.5% and a revenue growth 4.27% for ORGO